....

....

....

....

....

....

....

....

YSG has gapped up by 2.8% today on a volume of 1.5 million shares. This positive market reaction is driven by the announcement of positive Phase 2 clinical trial results for its lead drug candidate, increasing institutional investment, and broader positive sentiment within the biotechnology sector. Table of Contents Reasons for the Gap Up....

Zena Pharmaceuticals, Inc. (ZENA) has gapped up by 3.15% today on a volume of 8.7 million shares. This significant positive movement is driven by the announcement of positive Phase 2 clinical trial results for its lead drug candidate, ZN-101, combined with the receipt of FDA Fast Track designation. Table of Contents Reasons for the....